title: Clinical radioimmunotherapy--the role of radiobiology.
abstract: Conventional external-beam radiation therapy is dedicated to the treatment of localized disease, whereas radioimmunotherapy represents an innovative tool for the treatment of local or diffuse tumors. Radioimmunotherapy involves the administration of radiolabeled monoclonal antibodies that are directed specifically against tumor-associated antigens or against the tumor microenvironment. Although many tumor-associated antigens have been identified as possible targets for radioimmunotherapy of patients with hematological or solid tumors, clinical success has so far been achieved mostly with radiolabeled antibodies against CD20 ((131)I-tositumomab and (90)Y-ibritumomab tiuxetan) for the treatment of lymphoma. In this Review, we provide an update on the current challenges aimed to improve the efficacy of radioimmunotherapy and discuss the main radiobiological issues associated with clinical radioimmunotherapy.
authors: Direction de la Radioprotection de l'Homme, Institut de Radioprotection et de Sûreté Nucléaire, Fontenay-aux-Roses, F-92262, France. jean-pierre.pouget@inserm.fr
authors: Jean-Pierre
authors: JP
authors: Pouget
authors: Isabelle
authors: I
authors: Navarro-Teulon
authors: Manuel
authors: M
authors: Bardiès
authors: Nicolas
authors: N
authors: Chouin
authors: Guillaume
authors: G
authors: Cartron
authors: André
authors: A
authors: Pèlegrin
authors: David
authors: D
authors: Azria
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology*; D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D011853:Radiobiology; D016499:Radioimmunotherapy
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm